Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
I assign a HOLD rating, as STOK's pipeline is promising but high-risk, with significant milestones and regulatory hurdles ahead. The Biogen partnership secures funding through mid-2028 and positions STOK for potential M&A, but sacrifices some long-term international revenue. STOK's chronic annuity model and safety profile offer commercial advantages over one-time gene therapies, but trial and commercialization risks remain material. Andrii Dodonov/iStock via Getty Images Stoke Therapeutics, Inc. (NASDAQ: STOK ) stock is enjoying a great year. The past 6 months saw its stock gaining over 180%. Such gains could be already pricing in Phase 3 success of its lead pipeline. The company isn't just developing a drug but This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my ow
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual MeetingBusiness Wire
- Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual MeetingBusiness Wire
- Biotechs Are On A Big Run, And Two Stocks Have Buy Points [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
STOK
Earnings
- 11/4/25 - Miss
STOK
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- STOK's page on the SEC website